BIG
INMB icon

Brooklyn Investment Group’s INmune Bio INMB Stock Holding History

Brooklyn Investment Group’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-90
Closed -$208 – 1643
2025
Q2 		$208 Buy
+90
New +$660 ﹤0.01% 3191

Other funds holding INMB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Brooklyn Investment Group's INMB Position: Q3 2025 in Review

Brooklyn Investment Group sold out of INmune Bio (INMB) in Q3 2025, closing a stake of 90 shares — an estimated $208 sold.

Brooklyn Investment Group first reported a position in INMB in Q2 2025 and held it in 1 quarter. The position peaked at $208 in Q2 2025. 73 funds tracked by Wall St. Rank hold INMB as of Q3 2025.

  • Brooklyn Investment Group reported no remaining INmune Bio position as of Q3 2025 after selling out during the quarter.
  • Brooklyn Investment Group sold 90 INmune Bio shares in Q3 2025, an estimated $208.
  • Brooklyn Investment Group first reported a position in INmune Bio in Q2 2025 and held it in 1 quarter.
  • Brooklyn Investment Group's INmune Bio position peaked at $208 in Q2 2025.
  • 73 funds tracked by Wall St. Rank held INmune Bio as of Q3 2025.

Based on Brooklyn Investment Group's 13F filing for Q3 2025, filed 14 Nov 2025.